Amgen Inc. and partner UCB will file their osteoporosis drug romosozumab this year on the back of mostly positive Phase III data in postmenopausal women – but where will the drug be positioned against Amgen's own Prolia (denosumab) and other available treatments?
Amgen/UCB Poised For Osteoporosis Drug Filing On Back Of Mixed PhIII
Amgen Inc. and partner UCB will file their osteoporosis drug romosozumab this year on the back of mostly positive Phase III data in postmenopausal women – but where will the drug be positioned against Amgen's own Prolia (denosumab) and other available treatments?
More from Musculoskeletal
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
Encouraging results in younger children with Duchenne is keeping Regenxbio on track for a potential mid-2026 filing for its gene therapy, RGX-202.
• By
The gene therapy for Duchenne muscular dystrophy passed the blockbuster sales threshold in 2024. Analysts said the drug’s overall risk/benefit profile still appears solid.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
More from Therapy Areas
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.